Zurich based Araris Biotech is developing an ADC conjugation technology that allows for the use of multiple payload classes simultaneously
Acting CEO Dragan Grabulovski describes how they are able to achieve this, the benefits of having multiple payload classes at once, and the targets the company is currently working on.
Comments